to describe the prescribing trends for sodium valproate during and around pregnancy comparing 2016 with 2013
to describe the prescribing trends for alternative drugs during and around pregnancy comparing 2016 with 2013
women who became pregnant
using the french national health insurance database a crosssectional study was carried out in 2016 including women
using the french national health insurance database a crosssectional study was carried out in 2013 including women
women who had at least 1 reimbursement claim for sodium valproate in the 2 years prior to pregnancy
women who had at least 1 reimbursement claim for sodium valproate during pregnancy
exposure to sodium valproate was then measured in the 2 years before pregnancy after pregnancy
exposure to sodium valproate alternatives was then measured in the 2 years before pregnancy after pregnancy
exposure to sodium valproate was then measured in the year after pregnancy
exposure to sodium valproate alternatives was then measured during pregnancy after pregnancy
exposure to sodium valproate alternatives was then measured for each quarter after pregnancy
exposure to sodium valproate was then measured for each quarter after pregnancy
exposure to sodium valproate was then measured during pregnancy after pregnancy
exposure to sodium valproate alternatives was then measured in the year after pregnancy
among pregnant women with epilepsy the proportion decreased from 264 percent to 93 percent between 2016 alongside an increase in levetiracetam use
among pregnant women with epilepsy the proportion decreased from 264 percent to 93 percent between 2016 alongside an increase in lamotrigine use
among pregnant women with epilepsy the proportion decreased from 264 percent to 93 percent between 2013 alongside an increase in lamotrigine use
among pregnant women with epilepsy the proportion decreased from 264 percent to 93 percent between 2013 alongside an increase in levetiracetam use
the proportion exposed to sodium valproate during pregnancy
among pregnant women with bipolar disorder the proportion of women decreased from 37 percent in 2013 to 19 percent in 2016 without any switch to alternative drugs
women exposed during pregnancy
in both populations fewer than one third had consulted a specialist before pregnancy
fewer women exposed to sodium valproate during pregnancy
as recommended by the ema a change in practice over the 2013 to 2016 period was observed with fewer women
fewer women exposed before pregnancy
pregnancy which could suggest that the timing of pregnancy should be better planned when possible
however in 2016 a large number of women were exposed to sodium valproate in the first trimester of pregnancy